Clinical Edge Journal Scan

TNBC: Sacituzumab govitecan extends survival


 

Key clinical point: Sacituzumab govitecan improves survival vs. single-agent chemotherapy in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Sacituzumab govitecan vs. chemotherapy showed 59% and 52% reduction in the risk for progression and mortality, respectively ( P less than .001 for both). The objective response rate was 35% with sacituzumab govitecan and 5% with chemotherapy. Grade 3-4 adverse event rate was 64% and 47% in the sacituzumab govitecan and chemotherapy groups, respectively.

Study details: A phase 3 ASCENT study of patients with relapsed or refractory TNBC, randomly assigned to receive either sacituzumab govitecan or single-agent chemotherapy of physician’s choice.

Disclosures: The study was supported by Immunomedics, a subsidiary of Gilead Sciences. The authors received consulting fees outside this work.

Source: Bardia A et al. New Eng J Med. 2021 Apr 22. doi: 10.1056/NEJMoa2028485.

Recommended Reading

Clinical Edge Journal Scan Commentary: Breast Cancer April 2021
Breast Cancer ICYMI
Treating metastatic TNBC: Where are we now?
Breast Cancer ICYMI
Cancer screening stopped by pandemic: Repercussions to come?
Breast Cancer ICYMI
Steroid-refractory pneumonitis from ICIs: Experience at major centers
Breast Cancer ICYMI
Rankings of most common cancers to shift over next 20 years
Breast Cancer ICYMI
Personalized cancer vaccine shows early promise across tumor types
Breast Cancer ICYMI
Quicker fertility rebound in young women with breast cancer
Breast Cancer ICYMI
Cell-free DNA improves response prediction in breast cancer
Breast Cancer ICYMI
FDA panel backs atezolizumab for mTNBC – at least for now
Breast Cancer ICYMI
AHA statement flags CV risk of hormonal cancer therapies
Breast Cancer ICYMI